VMC Vulcan Materials Company
Vulcan Materials Company produces and supplies construction aggregates in the United States. It operates through three segments: Aggregates, Asphalt, and Concrete. The company provides crushed stone, sand and gravel, sand, and other aggregates for use in construction and maintenance of highways, streets, and other public works, as well as in the construction of housing and commercial, industrial, and other nonresidential facilities; aggregates that are used as ballast for construction and maintenance of railroad tracks; riprap and jetty stones for use in erosion control along roads and waterways; asphalt mix; asphalt construction paving services; and ready-mixed concrete products. The company was formerly known as Virginia Holdco, Inc. and changed its name to Vulcan Materials Company. Vulcan Materials Company was founded in 1909 and is headquartered in Birmingham, Alabama.…
Industry Peers
Building MaterialsKey Statistics
About Vulcan Materials Company (NYSE: VMC)
›
Vulcan Materials Company (NYSE: VMC) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Building Materials industry, part of the Basic Materials sector, and reports about 11,548 employees.
The shares were at 274.19 USD on 19 November 2026, down 1.9% over 52 weeks. Its 52-week range is 237.13 USD to 331.09 USD: the price is 17.2% below the high and 15.6% above the low.
At a market capitalisation of 35.19B USD, it trades at 32.4 times trailing earnings and 27.2 times forward earnings. The median trailing P/E of its 20 largest Building Materials peers is 17.5, a premium of 85% for VMC. It pays a dividend yielding 0.74% (it pays out 24% of its earnings), against a median of 1.59% among the dividend payers in that peer group.
Vulcan Materials Company reports return on equity of 12.6%, an operating margin of 19.8% and revenue down 4.7% year over year.
Its debt exceeds its cash by 5.22B USD, a debt-to-equity ratio of 0.57. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 313.61 USD is 14.4% above the current price. The next earnings report is expected on 16 February 2027.